Strong Q2 report, but guidance kept where it was. Dato-DXd was the main character in the conference call. Case unchanged, BUY and TP of SEK 1,662 (1,627).
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Author:
ABGSC Healthcare Research | Gonzalo Artiach
Pages:
13
Strong Q2 report, but guidance kept where it was. Dato-DXd was the main character in the conference call. Case unchanged, BUY and TP of SEK 1,662 (1,627).
